|Bid||8.31 x 1000|
|Ask||8.33 x 1000|
|Day's Range||8.05 - 8.39|
|52 Week Range||4.10 - 14.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.20|
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss Canopy Growth Corp (CGC), which begins trading on NYSE today and is the first pure cannabis play to achieve a listing on the exchange.
A federal judge questioned whether prosecutors can make racketeering charges stick against Insys Therapeutics Inc. founder John Kapoor and other officials accused of bribing doctors to prescribe the company’s opioid-based painkiller. U.S. District Judge Allison Burroughs challenged U.S. Justice Department prosecutors Tuesday to show how allegations Kapoor and other Insys executives used money and dinners to bribe doctors to boost sales of their Subsys painkiller would support a charge of racketeering, a statute created in the 1970s to help the government crack down on the mafia and other organized-crime outfits. The prosecutors allege Kapoor and other subordinates were using speaker’s fees to bribe doctors and finding ways to evade the U.S. Drug Enforcement Agency’s reviews of suspicious drug orders.
By Nate Raymond BOSTON (Reuters) - A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe an opioid and suggested U.S. prosecutors streamline the case to avoid its dismissal. U.S. District Judge Allison Burroughs in Boston said she believed the indictment did not contain enough allegations to support a racketeering conspiracy charge against billionaire Insys founder John Kapoor and six other former executives and managers. "The indictment has a core of conduct that's problematic and may be criminal," Burroughs said during a hearing.
A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe an opioid and suggested U.S. prosecutors streamline the case to avoid its dismissal. U.S. District Judge Allison Burroughs in Boston said she believed the indictment did not contain enough allegations to support a racketeering conspiracy charge against billionaire Insys founder John Kapoor and six other former executives and managers. "The indictment has a core of conduct that's problematic and may be criminal," Burroughs said during a hearing.
Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential HENDERSON, NV / ACCESSWIRE / ...
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on ICPT sign up now at www.wallstequities.com/registration. Biotech firms differ from conventional drug makers in that they utilize natural ingredients, as opposed to synthetic ones.
It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. Key FDA approvals in the first half included Amgen (NASDAQ:AMGN)/Novartis’s first CGRP antibody Aimovig/erenumab for prevention of migraine, Johnson & Johnson’s (NYSE:JNJ) next-generation oral androgen receptor (“AR”) inhibitor Erleada (apalutamide) for pre-metastatic prostate cancer (CRPC), Vertex Pharmaceuticals’ (NASDAQ:VRTX) third medicine to treat the underlying cause of CF, Symdeko, which is a combination of tezacaftor and ivacaftor and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU). FDA Decision on Indivior’s Schizophrenia Injection RBP-7000: On Jul 28, the FDA is expected to give its decision on Indivior‘s (OTCMKTS:INVVY) RBP-7000, which has been developed for the treatment of schizophrenia.
approaching the U.S launch of its long-awaited Epidiolex epilepsy medicine, the space for cannabis-based drugs to treat the disorder and other maladies is finally moving into reality. London-based GW Pharma said Monday (June 25) the U.S. Food and Drug Administration (FDA) has approved Epidiolex, a cannabinoid-based oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome -- both rare forms of epilepsy -- in patients at least two years old.
With an opioid summit hosted by the Food and Drug Administration just two days away, China's National Narcotic's Commission said June 25 that the United States needs to deal more effectively with demand for opioids. The statement, made by Liu Yuejin, deputy head of the agency at a press conference, was an indirect swipe at U.S. officials who have pointed at China's responsibility to cut off the flow of the synthetic drug fentanyl, an opioid that is far more powerful than standard opioid pain meds. It has become a more popular and deadly drug on the streets of the U.S. While fentanyl is manufactured and prescribed in the United States, what has medical and law enforcement officials as well politicians upset is the availability of illegally mailed fentanyl coming out of China and reaching the U.S.
Johnson Fistel, LLP is investigating potential violations of the federal and state securities laws on behalf of former stockholders of Ultratech, Inc. ("Ultratech"). Former investors, who held shares of Ultratech and received Veevo Instruments Inc. (VECO) ("Veevo ") shares resulting from the takeover, might have certain legal options.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reiterated its ongoing efforts to fundamentally transform the company. President and Chief Executive Officer Saeed Motahari joined INSYS in April 2017. Nearly 50 percent of the company’s field force are new to the company.
LAS VEGAS, NV / ACCESSWIRE / June 18, 2018 / President Donald Trump said recently that he was inclined to support a bipartisan effort in Congress to ease the U.S. ban on marijuana, a proposal that would ...
NEW YORK, NY / ACCESSWIRE / June 15, 2018 / U.S. market ended mostly higher on Thursday, as rallies from tech sector drove the Nasdaq to new intraday and closing records. The Dow Jones Industrial Average ...
Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely dose of epinephrine to avoid a potentially fatal outcome. INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. In a pharmacokinetics study involving 60 people with seasonal allergies, preliminary results showed that the bioavailability of the company’s novel, proprietary formulation of epinephrine delivered intranasally was similar to that of intramuscular injection with EpiPen® (0.3 mg).
Today, I will be analyzing INSYS Therapeutics Inc’s (NASDAQ:INSY) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affectRead More...
A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine. Dr. Michael Frey, 46, pleaded guilty on Monday in federal court in Fort Myers, Florida, to conspiring to receive kickbacks from a medical equipment provider and a pharmacy sales representative.
PHOENIX, June 04, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...
Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc, accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug. The lawsuit by Minnesota Attorney General Lori Swanson alleged that the company marketed the opioid drug intended to alleviate pain in cancer patients for unapproved uses. It added to the legal woes of Insys, whose former top executives have been caught up in a federal criminal investigation involving the drug, Subsys.
ST. PAUL, Minn. (AP) — Minnesota's attorney general is suing an Arizona-based pharmaceutical company, alleging it illegally marketed a painkiller made from the synthetic opioid fentanyl.
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted not to recommend approval of the company’s New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. “We appreciate the panelists’ perspective and guidance,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life.